Alnylam Pharma's total assets for Q3 2025 were $4.85B, an increase of 6.26% from the previous quarter. GB:0HD2 total liabilities were $4.62B for the fiscal quarter, a 7.01% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.